Urorec

Šalis: Armėnija

kalba: anglų

Šaltinis: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Prekės savybės Prekės savybės (SPC)
12-02-2015

Veiklioji medžiaga:

silodosin

Prieinama:

Recordati Industria Chimica e Farmaceutica S.p.A. Via M Civitali 1-20148 Milan for Recordati Ireland Ltd.

INN (Tarptautinis Pavadinimas):

silodosin

Dozė:

4mg

Vaisto forma:

capsules hard

Recepto tipas:

Prescription

Prekės savybės

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Urorec 4 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains 4 mg silodosin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
_ _
Yellow, opaque, hard gelatin capsule, size 3.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of the signs and symptoms of benign prostatic hyperplasia
(BPH).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is one capsule of Urorec 8 mg daily. For special
patient populations, one
capsule of Urorec 4 mg daily is recommended (see below).
_Elderly patients _
No dose adjustment is required in the elderly (see section 5.2).
_Renal impairment _
No dose adjustment is required for patients with mild renal impairment
(CL
CR
≥50 to ≤80 ml/min).
A starting dose of 4 mg once daily is recommended in patients with
moderate renal impairment (CL
CR
≥30 to <50 ml/min), which may be increased to 8 mg once daily after
one week of treatment,
depending on the individual patient’s response. The use in patients
with severe renal impairment
(CL
CR
<30 ml/min) is not recommended (see sections 4.4 and 5.2).
_ _
_Hepatic impairment _
No dose adjustment is required for patients with mild to moderate
hepatic impairment.
As no data are available, the use in patients with severe hepatic
impairment is not recommended (see
sections 4.4 and 5.2).
_Paediatric population _
There is no relevant use of Urorec in the paediatric population in the
indication.
Method of administration
The capsule should be taken with food, preferably at the same time
every day. The capsule should not
be broken or chewed but swallowed whole, preferably with a glass of
water.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
3
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Intraoperative Floppy Iris Syndrome (IFIS)
IFIS (a variant of small pupil syndrome) has been observed during
cataract
                                
                                Perskaitykite visą dokumentą
                                
                            

Dokumentai kitomis kalbomis

Pakuotės lapelis Pakuotės lapelis rusų 07-04-2018

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją